Skip to main content
. Author manuscript; available in PMC: 2013 May 9.
Published in final edited form as: Br J Haematol. 2008 Mar 26;141(4):433–444. doi: 10.1111/j.1365-2141.2008.06982.x

Fig 7.

Fig 7

Pair-mate analysis of patients treated with total therapy 2 (TT2) and total therapy 1 (TT1). Matching was done on cytogenetic abnormalities (CA), CRP (>8 mg/l) and creatinine (≥176.8 μmol/l), found to be the leading adverse variables in TT1. (A) Overall survival tended to be superior with TT2 versus TT1. (B) Event-free survival was superior with TT2 (both arms) versus TT1. (C) Duration of complete remission (CR) was superior with TT2 (both arms) versus TT1.